Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

por Zain, Jasmine, O’Connor, Owen A.
Publicado 2010

Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond

por Lue, Jennifer K., O’Connor, Owen A., Bertoni, Francesco
Publicado 2020

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

por Jain, Salvia, Diefenbach, Catherine, Zain, Jasmine, O’Connor, Owen A
Publicado 2011

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

por Oiwa, Kana, Hosono, Naoko, Nishi, Rie, Scotto, Luigi, O’Connor, Owen A., Yamauchi, Takahiro
Publicado 2021

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

por O’Connor, Owen A, Marchi, Enrica, Volinn, Weining, Shi, Jin, Mehrling, Thomas, Kim, Won Seog
Publicado 2018

A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib

por O'Neil, Daniel S., Francescone, Mark A., Khan, Karen, Bachir, Alobeid, O'Connor, Owen A., Sawas, Ahmed
Publicado 2018

Erratum to “A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib”

por O'Neil, Daniel S., Francescone, Mark A., Khan, Karen, Alobeid, Bachir, O'Connor, Owen A., Sawas, Ahmed
Publicado 2018

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

por Kinahan, Cristina, Mangone, Michael A., Scotto, Luigi, Visentin, Michele, Marchi, Enrica, Cho, Hearn Jay, O’Connor, Owen A.
Publicado 2020

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest

por Scotto, Luigi, Serrano, Xavier J., Zullo, Kelly, Kinahan, Cristina, Deng, Changchun, Sawas, Ahmed, Bates, Susan, O’Connor, Owen A.
Publicado 2020

Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

por Ma, Helen, Cheng, Bin, Montanari, Francesca, Lue, Jennifer K., Deng, Changchun, Marchi, Enrica, O’ Connor, Owen A., Sawas, Ahmed
Publicado 2020

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

por Kalac, Matko, Jain, Salvia, Tam, Constantine S., Xiao, Zhengrui, Montanari, Francesca, Kanakry, Jennifer, Huber, Bryan D., Goldfinger, Mendel, O’Connor, Owen A., Marchi, Enrica
Publicado 2023

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

por Falchi, Lorenzo, Sawas, Ahmed, Deng, Changchun, Amengual, Jennifer E., Colbourn, Donald S., Lichtenstein, Emily A., Khan, Karen A., Schwartz, Lawrence H., O’Connor, Owen A.
Publicado 2016

N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB

por Kalac, Matko, Mangone, Michael, Rinderspacher, Alison, Deng, Shi-Xian, Scotto, Luigi, Markson, Michael, Bansal, Mukesh, Califano, Andrea, Landry, Donald W., O'Connor, Owen A.
Publicado 2020

Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity

por Pal, Ipsita, Grilo, Andre M. Sardinha, Gaspary, Alec, Das Sharma, Sohani, Scotto, Luigi, O'Connor, Owen A., Jovanovic, Marko, Deng, Changchun, Berchowitz, Luke E.
Publicado 2022

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

por Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.
Publicado 2016

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

por Scotto, Luigi, Kinahan, Cristina, Casadei, Beatrice, Mangone, Michael, Douglass, Eugene, Murty, Vundavalli V., Marchi, Enrica, Ma, Helen, George, Changchun, Montanari, Francesca, Califano, Andrea, O'Connor, Owen A.
Publicado 2020

R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin

por Safari, Maryam, Litman, Thomas, Robey, Robert W., Aguilera, Andrés, Chakraborty, Arup R., Reinhold, William C., Basseville, Agnes, Petrukhin, Lubov, Scotto, Luigi, O'Connor, Owen A., Pommier, Yves, Fojo, Antonio T., Bates, Susan E.
Publicado 2021

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

por Ke, Hang, Zhang, Faming, Wang, Jingjing, Xiong, Lingxin, An, Xiaoyu, Tu, Xiaolong, Chen, Cen, Wang, Yueying, Mao, Binchen, Guo, Sheng, Ju, Cunxiang, He, Xiangfei, Sun, Ruilin, Zhang, Lei, O’Connor, Owen A., Li, Qi-Xiang
Publicado 2023

Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways

por Scotto, Luigi, Kinahan, Cristina, Douglass, Eugene, Deng, Changchun, Safari, Maryam, Casadei, Beatrice, Marchi, Enrica, Lue, Jennifer K., Montanari, Francesca, Falchi, Lorenzo, Qiao, Changhong, Renu, Nandakumar, Bates, Susan E., Califano, Andrea, O'Connor, Owen A.
Publicado 2021

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituxim...

por Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.
Publicado 2017